Table 3.
BHR, reversibility, symptom score, and exacerbations in COPD patients considered altogether and divided according to sputum eosinophils
| All patients (n=29) | Patients with eosinophils ≥3% (n=9) | Patients with eosinophils <3% (n=20) | P-value* | |
|---|---|---|---|---|
| BHR (μg) | 1,600 (208–1,600) | 100 (32–1,600) | 1,600 (990–1,600) | 0.010 |
| Reversibility (change FEV1 in %) | 5.6 (0.3–14.6) | 3.0 (0–21.1) | 5.9 (1.1–13.2) | 0.862 |
| Symptom score | 8.0 (5.0–10.0) | 8.0 (8.0–9.5) | 6.5 (4.2–9.5) | 0.031 |
| Exacerbations previous year | 0.0 (0.0–1.0) | 1.0 (1.0–1.5) | 0.0 (0.0–1.0) | 0.019 |
Notes: Values are expressed as median (interquartile range). Comparisons between variables were determined by unpaired t-test.
*
Patients with eosinophils ≥3% vs patients with eosinophils <3%.
Abbreviations: BHR, bronchial hyperresponsiveness; FEV1, forced respiratory volume in 1 second.